- Home
- LSEA vs ALDX Comparison
LSEA vs ALDX Comparison
Compare LSEA & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSEA
- ALDX
- Stock Information
- Founded
- LSEA 2013
- ALDX 2004
- Country
- LSEA United States
- ALDX United States
- Employees
- LSEA N/A
- ALDX N/A
- Industry
- LSEA Homebuilding
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- LSEA Consumer Discretionary
- ALDX Health Care
- Exchange
- LSEA Nasdaq
- ALDX Nasdaq
- Market Cap
- LSEA 300.4M
- ALDX 304.9M
- IPO Year
- LSEA N/A
- ALDX 2014
- Fundamental
- Price
- LSEA $7.04
- ALDX $6.76
- Analyst Decision
- LSEA Buy
- ALDX Strong Buy
- Analyst Count
- LSEA 4
- ALDX 2
- Target Price
- LSEA $13.75
- ALDX $10.00
- AVG Volume (30 Days)
- LSEA 437.1K
- ALDX 698.6K
- Earning Date
- LSEA 04-30-2025
- ALDX 05-01-2025
- Dividend Yield
- LSEA N/A
- ALDX N/A
- EPS Growth
- LSEA N/A
- ALDX N/A
- EPS
- LSEA 0.47
- ALDX N/A
- Revenue
- LSEA $1,550,337,000.00
- ALDX N/A
- Revenue This Year
- LSEA $4.04
- ALDX N/A
- Revenue Next Year
- LSEA $5.27
- ALDX N/A
- P/E Ratio
- LSEA $14.89
- ALDX N/A
- Revenue Growth
- LSEA 28.13
- ALDX N/A
- 52 Week Low
- LSEA $6.54
- ALDX $2.85
- 52 Week High
- LSEA $14.91
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- LSEA 42.42
- ALDX 54.11
- Support Level
- LSEA $6.79
- ALDX $6.22
- Resistance Level
- LSEA $7.79
- ALDX $6.87
- Average True Range (ATR)
- LSEA 0.34
- ALDX 0.44
- MACD
- LSEA 0.02
- ALDX -0.03
- Stochastic Oscillator
- LSEA 13.50
- ALDX 56.30
About LSEA Landsea Homes Corporation
Landsea Homes Corp is a homebuilding company. It designs and builds homes and sustainable master-planned communities in some of the nation's desirable markets. The company's segments include Arizona, California, Florida, Metro New York, and Texas. It derives a majority of revenue from home sales in Florida.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.